Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

Summary

The goal of this clinical research study is to find the highest tolerable dose of radium-223 dichloride that can be given to patients with osteosarcoma. Radium-223 chloride is designed to work like radiation therapy in cells that are actively making bone. It is designed to target new bone growth in and around bone cancer and may kill cancer cells.

Timeline

Start

2013-10-16

Primary completion

2020-04-08

Completion

2020-04-08

Publications

• Subbiah V, Anderson P, Rohren E. Alpha Emitter Radium 223 in High-Risk Osteosarcoma: First Clinical Evidence of Response and Blood-Brain Barrier Penetration. JAMA Oncol. 2015 May;1(2):253-5. doi: 10.1001/jamaoncol.2014.289. No abstract available.

Drugs

Indications